



MICHAEL J SECKL

United Kingdom

Personal statement

It would be an honour and pleasure to be able to serve and contribute on the ESGO council. I will bring a wealth of experience from serving on many national and international committees/ councils and societies acting as chairperson, president, secretary and treasurer amongst other roles.

I have a large international network of collaborators from many disciplines and am well practiced in working with people to achieve common goals that have helped women across the globe to achieve better outcomes for their gynaecological cancers.

My particular interest has been gestational trophoblastic disease where my home team are the international leaders in the field. I fully understand that without team work across the UK, this and my establishment of a new national malignant ovarian germ cell tumour service could not have been achieved. I have always enjoyed working with others and trying to converse in other languages even if it is at a basic level.

I am passionate about research and education and do this both locally, nationally and internationally. Education is essential because individuals like myself do not work forever. We must therefore help establish a new cadre of highly motivated well-trained doctors, nurses and other healthcare professionals who can continue the development of existing and new services for patients who are at the heart of everything we do.

Accreditation of services to recognise excellence is also essential and helps patients to know they are getting the best care possible.

In short, I will bring energy, enthusiasm, experience, wisdom and strong diplomacy skills and look forwards to the opportunity to help ESGO exceed in its current mission and goals.

Curriculum Vitae

Professor Michael J Seckl

Qualifications

2017	FMedSci	Academy of Medical Sciences
2000	FRCP	Royal College of Physicians
1995	PhD – Biochemistry	University of London
1990	MRCP	Royal College of Physicians
1986	MB BS	University of London
1983	BSc 2.1 - Immunology	University of London

Employment history

Feb 2018-present	Head of Imperial Cancer Trials Unit	Dept Surgery and Cancer Imperial College London
June 2012 - Oct 2022	Director of Postgraduate Studies	Dept Surgery and Cancer Imperial College London
June 2007- Apr 2022	PI/Lead of Imperial Experimental Cancer Medicine Centre	Dept Surgery and Cancer Imperial College London
Oct 2002-present	Professor of Molecular Oncology Director of Charing Cross Trophoblastic Disease Service	Imperial College Healthcare NHS Trust, Dept of Cancer Medicine, Imperial College London
Oct 2000– Oct 2002	Reader in Cancer Medicine, Head of Lung Cancer Biology Group	Dept of Cancer Medicine, Imperial College London
Sept 1995-Oct 2000	Senior Lecturer in Medical Oncology	Dept of Cancer Medicine, Imperial College London
Sept 1991-1995	ICRF Clinical Research Fellow/ Senior Registrar	ICRF LIF/ Royal Free Hospital, London

Selected Grants: Total Income last 5 yrs: £14.45M (Excl Natl Service) PI:£7.41M £

Apr 2012-17	CR-UK/NIHR Imperial ECMC (PI)	1M
Apr 2017-23	CR-UK/NIHR Imperial ECMC (PI)	2.3M
Apr 2017-22	CR-UK Imperial Centre grant (Co-PI)	2.6M
Oct 2017-21	MRC DTP iCASE award (PI)	140K
Oct 2021-25	MRC DTP iCASE award (PI)	140K
Aug 2016-26	CTRT award (PI)	550K
Sep 2021-29	NIHR REFINE-Lung Phase 3 trial (PI)	3.15M
Oct 2021-25	Lung Cancer Research award (Co-PI)	430K
Mar 2023-25	Lung Cancer Research award (Co-PI)	100K
Jul 2023-26	June Hancock Mesothelioma Research Fund	250K
Jul 2025-28	Wellbeing award for ETT/PSTT genetics (Co-PI)	300K

Also: PI for £2M/yr National Choriocarcinoma Service at Charing Cross grant from DoH
Primary supervisor for £1.3M CR-UK clinician scientist award Apr '23-'28

National and International Roles (selected examples)

President of the Royal Society of Medicine Oncology Section (2020-2022)
Member of numerous previous grant committees including Medical Research Council, Cancer Research-UK and National Institute for Health Research
Chair of Pancreatic Cancer Charity grants committee (2008-2023)
Prior editorial board membership of several journals including Cancer Research
Established and continue to Co-Chaired Gynae theme for European Rare Adult Cancer Network-EURACAN (2017- present)
Past secretary, president and current treasurer of the International Society for the Study of Trophoblastic Disease (2005-present)
Co-Founder of the European Organisation for the Treatment of Trophoblastic Disease, prior secretary, president and current board member (2009-present)

Selected relevant publications

Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, Newlands ES. (2000) Choriocarcinoma and partial hydatidiform moles. *Lancet* 356; 36-39

Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, Newlands ES, **Seckl MJ**. (2002) Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin *Lancet* Jun 22; 359(9324): 2165-6

Seckl MJ, Gillmore R, Foskett M, Sebire NJ, Rees H, Newlands. ES, (2004) Routine terminations of Pregnancy – Should we screen for Gestational Trophoblastic Neoplasia? *Lancet* Aug 21;364(9435):705-7

Palmieri C, Fisher RA, Sebire NJ, Lindsay I, Smith JR, McGluggage WG, Savage P, **Seckl MJ** (2005) Placental site trophoblastic tumour arising from a partial hydatidiform mole: the importance of β -hCG surveillance. *Lancet* 366; 688

Pfeffer PE, Sebire N, Lindsay I, McIndoe A, Lim A, **Seckl MJ** (2007) Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour. *Lancet Oncol* Aug;8(8):744-6

Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, **Seckl MJ** (2008) Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). *Ann Oncol*. Sep;19(9):1578-83

Schmid P, Nagai Y, Agarwal R, Hancock BW, Savage PM, Sebire NJ, Lindsay I, Wells M, Fisher RA, Short D, Newlands ES, Wischnewsky MB, **Seckl MJ**. (2009) Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. *Lancet* Jul 4;374(9683):6-7

Seckl MJ, Sebire NJ and Berkowitz R (2010) Gestational trophoblastic disease. *Lancet* 28;376(9742):717-29

Fisher RA, Lavery SA, Carby A, Abu-Hayyeh S, Swingler R, Sebire NJ, **Seckl MJ** (2011) What a difference an egg makes. *Lancet* Dec 3;378(9807):1974

Agarwal R, Teoh S, Short D, Harvey R, Savage PM, **Seckl MJ** (2012) Elevated human chorionic gonadotrophin levels six months after uterine evacuation of molar pregnancy- is chemotherapy necessary? A retrospective cohort study. *Lancet* Mar 13;106(6):1089-94

Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, **Seckl MJ**. (2013) EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. *J Clin Oncol*; 31(2):280-6

Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C; ESMO Guidelines Working Group (2013) Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013 Oct;24 Suppl 6:vi39-50

Roy R, Sclanders M, Hue L, Skehel M, Mauri F, Jordan LE, Lin G, Holcik M, **Seckl MJ***, and Pardo OE* . (2014) FGF-2/S6K2 signalling regulates hnRNPA1 nuclear-cytoplasmic shuttling to enhance translation of BCL-XL and XIAP. *corresponding authors *Nucleic Acid Research* Nov 10;42(20):12483-97

Savage P, Cooke R, O'Nions J, Krell J, Kwan A, Camarata M, Dancy G, Short D, **Seckl MJ**, Swerdlow A. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. *J Clin Oncol*. 2015 Feb 10;33(5):472-8.

Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). *J Clin Oncol*. 2017;35(14):1506-1514

Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Akarca A, Marafioti T, Quezada S, Sarwar N, **Seckl MJ**. Pembrolizumab induces long term complete remission of chemotherapy resistant gestational trophoblastic neoplasia. *Lancet* 2017; 390(10110):2343-2345

Eysbouts YK, Ottevanger PB, Massuger LFAG, IntHout J, Short D, Harvey R, Kaur B, Sebire NJ, Sarwar N, Sweep FCGJ, Seckl MJ. Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia (GTN) be simplified? A new retrospective analysis from a nationwide data-set.

Ann Oncol. 2017 Apr 28. doi: 10.1093/annonc/mdx211

Frijstein MM, Lok CAR, Short D, Singh K, Fisher RA, Hancock BW, Tidy JA, Sarwar N, Kanfer E, Winter MC, Savage PM, **Seckl MJ**. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. *Eur J Cancer*. 2019 Mar;109:162-171

Braga A, Paiva G, Ghorani E, Freitas F, Velarde LGC, Kaur B, Unsworth N, Lozano-Kuehne J, Vieira dos Santos Esteves AP, Filho JR, Junior JA, Aguiar X, Sarwar N, Elias KM, Horowitz NS, Berkowitz RS, **Seckl MJ**. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: an international, multicentre, retrospective study. *Lancet Oncol* 2021 22(8):1188-1198

Chrysostomou S, Roy R, Prischi F, Thamlikitkul L, Chapman KL, Mufti U, Peach R, Ding L, Hancock D, plus 28 others, Downward J, Skehel JM, Ali MMU, **Seckl MJ***, Pardo OE*. Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. *corresponding authors. *Sci Transl Med*. 2021 Jul 14;13(602):eaba4627. doi: 10.1126/scitranslmed.aba4627

Georgiou M, Ntavelou P, Stokes W, Roy R, Maher GJ, Stoilova T, Choo JAMY, Rakhit CP, Martins M, Ajuh P, Horowitz N, Berkowitz RS, Elias K, **Seckl MJ**, Pardo OE. ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.

Oncogene. 2022 Apr;41(18):2540-2554.

Maher GJ, Fisher RA, Kaur B, Aguiar X, Aravind P, Cedeno N, Clark J, Damon D, Ghorani E, Januszewski A, Kalofonou F, Murphy R, Roy R, Sarwar N, Openshaw MR, **Seckl MJ**. Sensitive screening of single nucleotide polymorphisms in cell free DNA for diagnosis of gestational tumours. *NPJ Genom Med*. 2022 Apr 8;7(1):26.

Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong A, Allerton R, Landers D, Nicholas H, McLellan L, Lim A, Mouliere F, Pardo OE, Ferguson V, **Seckl MJ**. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. *Nat Commun*. 2022 Jun 10;13(1):3246.

Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O'Brien M, Ottensmeier C, Pizzo E, Spicer J, Williams A, Badman P, Parmar MKB, **Seckl MJ**. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. *Lancet Oncol*. 2023 May;24(5):e219-e227

Bergamini A, Ramaswami R, Froeling F, Papanastasopoulos P, Short D, Aguiar X, Savage PM, Sarwar N, Kaur B, Sasso S, Fotopoulou C, Sharma A, Rustin GJS, **Seckl M**. Fertility outcomes following surgery and multiagent chemotherapy in malignant ovarian germ cell tumor survivors: a survey study. *Int J Gynecol Cancer*. 2023 Nov 6;33(11):1750-1756. PMID: 37931975

Parker VL, Winter MC, Tidy JA, Palmer JE, Sarwar N, Singh K, Aguiar X, Hancock BW, Pacey AA, **Seckl MJ**, Harrison RF. PREDICT-GTN 2: Two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia. *Gynecol Oncol*. 2024 Jan;180:152-159. PMID: 38091775

Swift BE, Coopmans L, Singh K, Coyle C, Wilkes EH, Jabbar I, Maher G, Aguiar X, Salman L, Palmer JE, Sarwar N, Caldwell R, Ghorani E, Kaur B, van Trommel NE, Lok CAR, Winter M, **Seckl MJ**. Monitoring complete hydatidiform molar pregnancies after normalisation of human chorionic gonadotrophin: national retrospective population study. *BMJ Med*. 2025 Apr 23;4(1):e001017. PMID: 40309224

Seckl MJ, Kaur B, Ghorani E, Bergamini A, Mangili G Controversies in malignant ovarian germ cell tumors. *Int J Gynecol Cancer*. 2025 Mar;35(3):101670

Lok C, N.E. van Trommel NE, Braicu EI, Planchamp F, Berkowitz R, **Seckl MJ** on behalf of the EOTTD-ESGO-GCIG-ISSTD guideline committee EOTTD-ESGO-GCIG-ISSTD practical guidelines for the treatment of gestational trophoblastic disease *J Clin Oncol* 2025 Jun 20;43(18):2119-2128.

Seckl MJ, Ghorani E. Current and future treatments for low-risk gestational trophoblastic neoplasia. *Ann Oncol*. 2025 Oct;36(10):1111-1112